GLP-1 and diabetic nephropathy share key molecular targets

Area of Science:

• Molecular biology
• Genomics
• Pharmacology

Background:

• Glucagon-like peptide-1 (GLP-1) receptor agonists demonstrate renoprotective effects in diabetic patients.
• The precise molecular mechanisms connecting GLP-1 signaling to diabetic nephropathy are not well understood.

Purpose of the Study:

• To identify common molecular targets between GLP-1 activity and diabetic kidney disease.
• To elucidate the molecular pathways involved in GLP-1's renoprotective effects.

Main Methods:

• Integrated protein targets of GLP-1 (UniProt) with diabetic kidney disease-associated genes (GeneCards).
• Analyzed overlapping genes using STRING and Cytoscape for network clustering (MCODE).
• Performed Gene Ontology and KEGG enrichment analysis and molecular docking (HADDOCK) to validate interactions.

Main Results:

• Identified 17 shared genes, including STAT3, EP300, MAPK1, and INSR, forming a key network cluster.
• This cluster is significantly enriched in pathways related to insulin response, hypoxia adaptation, apoptosis, and glucose metabolism.
• Molecular docking confirmed direct binding of GLP-1 to STAT3, PIK3R1, and EP300, suggesting non-canonical mechanisms.

Conclusions:

• Revealed a novel convergence between GLP-1 signaling and diabetic nephropathy pathways.
• Provided mechanistic insights into GLP-1's renoprotective effects, involving transcriptional regulation and epigenetic modulation.
• This framework may aid in developing refined renal therapies targeting GLP-1 modulation.